Expression and prognostic significance of human peroxiredoxin isoforms in endometrial cancer

We evaluated the expression of Prx isoforms in normal endometrium, endometrial hyperplasia and endometrial cancer

SEULHEE HAN; HAIYING SHEN; MINHYUNG JUNG; BUM-SOO HAHN; BYUNG KWAN JIN; INSUG KANG; JOOHUN HA; WONCHAE CHOE

2012

Scholarcy highlights

  • Endometrial cancer is the most frequent gynecological malignancy in the world
  • Each sample was classified into 3 groups: normal endometrium, endometrial hyperplasia and endometrial cancer
  • To determine whether the expression level of Prx I is associated with endometrial cancer development, we examined the immunohistochemical expression of Prx I in endometrial cancer tissue
  • We investigated whether the expression of the Prx isoforms served as a prognostic biomarker for endometrial cancer by using the follow-up data of surgically treated endometrial cancer patients
  • The Prx V expression group was divided into the low Prx V expression group, which included the patients with a weak or moderate Prx V expression, and the high Prx V expression group, which included the patients with a strong Prx V expression, in endometrial cancer samples
  • 55.6 and 44.4% of the samples demonstrated a negative and weak expression of Prx III, respectively
  • Prx III, IV and V are known to be upregulated in breast malignancy, while in colorectal neoplasms, Prx I, II, III and V are elevated, and recently, it was reported that Prx III and IV are consistently upregulated in prostate cancer
  • We have demonstrated that Prx III and V are preferentially overexpressed in human endometrial carcinoma, and the expression levels are associated with tumor grade

Need more features? Save interactive summary cards to your Scholarcy Library.